Tim Christen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Tim Christen has a total of 190 co-authors. Here are the top co-authors by number of shared publications:
Frits R. Rosendaal
Department of Clinical Epidemiology, Leiden University Medical Center (LUMC), PO-Box 9600, 2300RC, Leiden, The Netherlands
6 shared publicationsJ. Wouter Jukema
Department of Cardiology, LUMC, PO-Box 9600, 2300RC, Leiden, The Netherlands
5 shared publicationsRenée de Mutsert
Department of Clinical Epidemiology, Leiden University Medical Centre (LUMC), Leiden, The Netherlands
5 shared publicationsStella Trompet
Department of Internal Medicine, Section of Gerontology and Geriatrics, PO-Box 9600, 2300RC, LUMC, Leiden, The Netherlands; Department of Cardiology, LUMC, PO-Box 9600, 2300RC, Leiden, The Netherlands
4 shared publicationsHildo J. Lamb
Department of Radiology, LUMC, Leiden, the Netherlands
3 shared publicationsKo Willems van Dijk
Department of Human Genetics, LUMC, PO-Box 9600, 2300RC, Leiden, The Netherlands; Department of Medicine, Division of Endocrinology, LUMC, PO-Box 9600, 2300RC, Leiden, The Netherlands; Einthoven Laboratory for Vascular and Regenerative Medicine, LUMC, PO-Box 9600, 2300RC, Leiden, The Netherlands
3 shared publications
Latest Publications
- Open Access
- 23 February 2023
- Published by Elsevier in Nutrition, Metabolism and Cardiovascular Diseases
- Vol. 33 (5) , 1077-1086
The association between leptin and subclinical cardiovascular disease explained by body fat: Observational and Mendelian randomization analyses
- 23 February 2023
- Published by Elsevier in Nutrition, Metabolism and Cardiovascular Diseases
- Vol. 33 (5) , 1077-1086
Open AccessThe association between leptin and subclinical cardiovascular disease explained by body fat: Observational and Mendelian randomization analyses
- 1 July 2019
- Published by Elsevier in Nutrition, Metabolism and Cardiovascular Diseases
- Vol. 29 (7) , 728-735
The role of inflammation in the association between overall and visceral adiposity and subclinical atherosclerosis
- 1 July 2019
- Published by Elsevier in Nutrition, Metabolism and Cardiovascular Diseases
- Vol. 29 (7) , 728-735
The role of inflammation in the association between overall and visceral adiposity and subclinical atherosclerosis
- 1 May 2018
- Published by Wolters Kluwer Health in Circulation: Genomic and Precision Medicine
- Vol. 11 (5) , e002034
CETP (Cholesteryl Ester Transfer Protein) Concentration
Background: We aimed to identify independent genetic determinants of circulating CETP (cholesteryl ester transfer protein) to assess causal effects of variation in CETP concentration on circulating lipid concentrations and cardiovascular disease risk. Methods: A genome-wide association discovery and replication study on serum CETP concentration were embedded in the NEO study (Netherlands Epidemiology of Obesity). Based on the independent identified variants, Mendelian randomization was conducted on serum lipids (NEO study) and coronary artery disease (CAD; CARDIoGRAMplusC4D consortium). RESULTS: In the discovery analysis (n=4248), we identified 3 independent variants ( P −8 ) that determine CETP concentration. These single-nucleotide polymorphisms were mapped to CETP and replicated in a separate subpopulation (n=1458). Per-allele increase (SE) in serum CETP was 0.32 (0.02) µg/mL for rs247616-C, 0.35 (0.02) µg/mL for rs12720922-A, and 0.12 (0.02) µg/mL for rs1968905-G. Combined, these 3 variants explained 16.4% of the total variation in CETP concentration. One microgram per milliliter increase in genetically determined CETP concentration strongly decreased high-density lipoprotein cholesterol (−0.23 mmol/L; 95% confidence interval, −0.26 to −0.20), moderately increased low-density lipoprotein cholesterol (0.08 mmol/L; 95% confidence interval, 0.00–0.16), and was associated with an odds ratio of 1.08 (95% confidence interval, 0.94–1.23) for CAD risk. Conclusions: This is the first genome-wide association study identifying independent variants that largely determine CETP concentration. Although high-density lipoprotein cholesterol is not a causal risk factor for CAD, it has been unequivocally demonstrated that low-density lipoprotein cholesterol lowering is proportionally associated with a lower CAD risk. Therefore, the results of our study are fully consistent with the notion that CETP concentration is causally associated with CAD through low-density lipoprotein cholesterol.
- 1 May 2018
- Published by Wolters Kluwer Health in Circulation: Genomic and Precision Medicine
- Vol. 11 (5) , e002034
CETP (Cholesteryl Ester Transfer Protein) Concentration
Background: We aimed to identify independent genetic determinants of circulating CETP (cholesteryl ester transfer protein) to assess causal effects of variation in CETP concentration on circulating lipid concentrations and cardiovascular disease risk. Methods: A genome-wide association discovery and replication study on serum CETP concentration were embedded in the NEO study (Netherlands Epidemiology of Obesity). Based on the independent identified variants, Mendelian randomization was conducted on serum lipids (NEO study) and coronary artery disease (CAD; CARDIoGRAMplusC4D consortium). RESULTS: In the discovery analysis (n=4248), we identified 3 independent variants ( P −8 ) that determine CETP concentration. These single-nucleotide polymorphisms were mapped to CETP and replicated in a separate subpopulation (n=1458). Per-allele increase (SE) in serum CETP was 0.32 (0.02) µg/mL for rs247616-C, 0.35 (0.02) µg/mL for rs12720922-A, and 0.12 (0.02) µg/mL for rs1968905-G. Combined, these 3 variants explained 16.4% of the total variation in CETP concentration. One microgram per milliliter increase in genetically determined CETP concentration strongly decreased high-density lipoprotein cholesterol (−0.23 mmol/L; 95% confidence interval, −0.26 to −0.20), moderately increased low-density lipoprotein cholesterol (0.08 mmol/L; 95% confidence interval, 0.00–0.16), and was associated with an odds ratio of 1.08 (95% confidence interval, 0.94–1.23) for CAD risk. Conclusions: This is the first genome-wide association study identifying independent variants that largely determine CETP concentration. Although high-density lipoprotein cholesterol is not a causal risk factor for CAD, it has been unequivocally demonstrated that low-density lipoprotein cholesterol lowering is proportionally associated with a lower CAD risk. Therefore, the results of our study are fully consistent with the notion that CETP concentration is causally associated with CAD through low-density lipoprotein cholesterol.
- 1 January 2018
- Published by Elsevier in Journal of Clinical Lipidology
- Vol. 12 (1) , 137-144.e1
Mendelian randomization analysis of cholesteryl ester transfer protein and subclinical atherosclerosis: A population-based study
- 1 January 2018
- Published by Elsevier in Journal of Clinical Lipidology
- Vol. 12 (1) , 137-144.e1
Mendelian randomization analysis of cholesteryl ester transfer protein and subclinical atherosclerosis: A population-based study
- 1 August 2017
- Published by Elsevier in Atherosclerosis
- Vol. 263, e74
No association between CETP concentration and intima media thickness in the general population: The Neo study
- 1 August 2017
- Published by Elsevier in Atherosclerosis
- Vol. 263, e74
No association between CETP concentration and intima media thickness in the general population: The Neo study
- Top Cited PapersOpen Access
- 1 February 2017
- Published by Elsevier in The Lancet Diabetes & Endocrinology
- Vol. 5 (2) , 97-105
PCSK9 genetic variants and risk of type 2 diabetes: a mendelian randomisation study
- 1 February 2017
- Published by Elsevier in The Lancet Diabetes & Endocrinology
- Vol. 5 (2) , 97-105
Top Cited PapersOpen AccessPCSK9 genetic variants and risk of type 2 diabetes: a mendelian randomisation study
- Open Access
- 1 May 2014
- Published by Springer Nature in British Journal of Cancer
- Vol. 110 (12) , 2935-2944
Clinical prognostic value of combined analysis of Aldh1, Survivin, and EpCAM expression in colorectal cancer
Tumour aggressiveness might be related to the degree of main cancer hallmark acquirement of tumour cells, reflected by expression levels of specific biomarkers. We investigated the expression of Aldh1, Survivin, and EpCAM, together reflecting main cancer hallmarks, in relation to clinical outcome of colorectal cancer (CRC) patients. Immunohistochemistry was performed using a tumour tissue microarray of TNM (Tumour, Node, Metastasis)-stage I–IV CRC tissues. Single-marker expression or their combination was assessed for associations with the clinical outcome of CRC patients (N=309). Increased expression of Aldh1 or Survivin, or decreased expression of EpCAM was each associated with poor clinical outcome, and was therefore identified as clinically unfavourable expression. Analyses of the combination of all three markers showed worse clinical outcome, specifically in colon cancer patients, with an increasing number of markers showing unfavourable expression. Hazard ratios ranged up to 8.3 for overall survival (PPP<0.001). Our data identified combined expression levels of Aldh1, Survivin, and EpCAM as strong independent prognostic factors, with high hazard ratios, for survival and tumour recurrence in colon cancer patients, and therefore reflect tumour aggressiveness.
- 1 May 2014
- Published by Springer Nature in British Journal of Cancer
- Vol. 110 (12) , 2935-2944
Open AccessClinical prognostic value of combined analysis of Aldh1, Survivin, and EpCAM expression in colorectal cancer
Tumour aggressiveness might be related to the degree of main cancer hallmark acquirement of tumour cells, reflected by expression levels of specific biomarkers. We investigated the expression of Aldh1, Survivin, and EpCAM, together reflecting main cancer hallmarks, in relation to clinical outcome of colorectal cancer (CRC) patients. Immunohistochemistry was performed using a tumour tissue microarray of TNM (Tumour, Node, Metastasis)-stage I–IV CRC tissues. Single-marker expression or their combination was assessed for associations with the clinical outcome of CRC patients (N=309). Increased expression of Aldh1 or Survivin, or decreased expression of EpCAM was each associated with poor clinical outcome, and was therefore identified as clinically unfavourable expression. Analyses of the combination of all three markers showed worse clinical outcome, specifically in colon cancer patients, with an increasing number of markers showing unfavourable expression. Hazard ratios ranged up to 8.3 for overall survival (PPP<0.001). Our data identified combined expression levels of Aldh1, Survivin, and EpCAM as strong independent prognostic factors, with high hazard ratios, for survival and tumour recurrence in colon cancer patients, and therefore reflect tumour aggressiveness.